公开(公告)号：US20250127814A1

公开(公告)日：2025-04-24

申请号：US18695701

申请日：2022-10-06

Applicant: THE UNIVERSITY OF CHICAGO

Inventor： Anthony KOSSIAKOFF ,  Annika SÄÄF ,  Marcin URA ,  Somnath MUKHERJEE

IPC: A61K35/17 ,  A61K40/11 ,  A61K40/15 ,  A61K40/31 ,  A61K40/42 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/85 ,  G01N33/573 ,  G01N33/58

Abstract: Aspects of the present disclosure are directed to borealin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such borealin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using borealin-targeting polypeptides.

公开(公告)号：US20250018038A1

公开(公告)日：2025-01-16

申请号：US18695590

申请日：2022-10-06

Applicant: THE UNIVERSITY OF CHICAGO

Inventor： Anthony KOSSIAKOFF ,  Annika SÄÄF ,  Marcin URA ,  Somnath MUKHERJEE

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/18 ,  G01N33/574

Abstract: Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.

公开(公告)号：US20240199757A1

公开(公告)日：2024-06-20

申请号：US18590875

申请日：2024-02-28

Applicant: THE UNIVERSITY OF CHICAGO

Inventor： Anthony KOSSIAKOFF ,  Carla E. MEINTS ,  Somnath MUKHERJEE

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2896 ,  A61P35/00 ,  G01N33/57484 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: Aspects of the present disclosure are directed to NT5E (CD73)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such NT5E-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of cancer using NT5E-targeting polypeptides.

公开(公告)号：US20180334494A1

公开(公告)日：2018-11-22

申请号：US15518417

申请日：2015-10-16

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION ,  THE UNIVERSITY OF CHICAGO

Inventor： Zygmunt S. DEREWENDA ,  Daniel A. ENGEL ,  Anthony KOSSIAKOFF ,  Elena K. DAVYDOVA ,  Mateusz JASKOLOWSKI

IPC: C07K16/10 ,  G01N33/569

CPC classification number: C07K16/10 ,  A61K39/42 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2333/08

Abstract: This disclosure is directed to compositions and methods for utilizing the boundaries of the C-terminal domains of Nucleoprotein from Zaire Ebola virus as highly stable recombinant protein antigens to generate antibodies for diagnosis and treatment of Ebola virus infection.

公开(公告)号：US20240408138A1

公开(公告)日：2024-12-12

申请号：US18697566

申请日：2022-10-06

Applicant: THE UNIVERSITY OF CHICAGO

Inventor： Anthony KOSSIAKOFF ,  Annika SÄÄF ,  Marcin URA ,  Somnath MUKHERJEE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  G01N33/543 ,  G01N33/574

Abstract: Aspects of the present disclosure are directed to INCENP-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such INCENP-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using INCENP-targeting polypeptides.

公开(公告)号：US20240059760A1

公开(公告)日：2024-02-22

申请号：US18251351

申请日：2021-11-01

Applicant: The University of Chicago

Inventor： Anthony KOSSIAKOFF ,  Tomasz SLEZAK

IPC: C07K16/10 ,  A61P31/14 ,  G01N33/569

CPC classification number: C07K16/1003 ,  A61P31/14 ,  G01N33/56983 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/626 ,  G01N2333/165

Abstract: Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.

公开(公告)号：US20240043534A1

公开(公告)日：2024-02-08

申请号：US17754797

申请日：2020-10-14

Applicant: The University of Chicago

Inventor： Anthony KOSSIAKOFF ,  Tomasz SLEZAK ,  Elena DAVYDOVA ,  Edwin ARAUZ-DIAZ

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2809 ,  C07K16/2887 ,  A61P35/00 ,  C07K16/2803 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2319/03

Abstract: The engineered polypeptide comprising modified Fab constant regions and/or protein G Fab binding domains provide advanced affinity reagents that can be used in cell biology applications as well as for therapeutic applications. Accordingly, aspects of the disclosure relate to a polypeptide comprising a constant region of an antibody light chain, wherein the constant region comprises a substitution/deletion of amino acids corresponding to positions 16-20 of SEQ ID NO:1 of the constant region with the amino acids LRT.